Dr. Paczesny is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1044 W. Walnut Street
R4-425
Indianapolis, IN 46202Phone+1 317-278-5487
Summary
- Dr. Sophie Paczesny is a pediatric hematologist/oncologist in Indianapolis, IN. She received her medical degree from University of Paris VII Faculty of Medicine and has been in practice 21 years. She specializes in cancer genetics/cancer risk assessment and pediatric hematologic oncology.
Education & Training
- University of Paris VII Faculty of MedicineClass of 1995
Clinical Trials
- Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease Start of enrollment: 2014 Jan 01
- Sinusoidal Obstruction Syndrome for Stem Cell Transplant Patients Biomarker Study Start of enrollment: 2017 Apr 01
Publications & Presentations
PubMed
- 11 citationsST2/MyD88 Deficiency Protects Mice against Acute Graft-versus-Host Disease and Spares Regulatory T Cells.Brad Griesenauer, Hua Jiang, Jinfeng Yang, Jilu Zhang, Abdulraouf Ramadan
Journal of Immunology. 2019-05-15 - 83 citationsLong-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cellsJoseph W. Fay, A. Karolina Palucka, Sophie Paczesny, Madhav V. Dhodapkar, Dennis A. Johnston
Cancer Immunology, Immunotherapy. 2006-10-01 - 45 citationsImmunotherapy via dendritic cellsA. Karolina Palucka, Beatrice Laupeze, Caroline Aspord, Hiroaki Saito, Gaetan Jego
Advances in Experimental Medicine and Biology. 2005-01-01
Journal Articles
- Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value in Isolation or with Other Graft-Versus-Host Disease Symptoms as Currently Diagnos...Margaret MacMillan, Sophie Paczesny, Ran Reshef, Daniel Weisdorf, Haematologica
- From Proteomics to Discovery of First-in-Class ST2 Inhibitors Active in VivoSophie Paczesny, MD, The Journal of Clinical Investigation
Press Mentions
- Risk Biomarkers May Be Used to Anticipate Severe Stem Cell Transplant Adverse Effects: ResearchMay 28th, 2023
- Risk Biomarkers Could Predict Serious Side Effect of Stem Cell TransplantMay 22nd, 2023
- Golden Appointed to Diversity, Inclusion and Equity CommitteeMarch 29th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: